



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
611 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TEXAS 76011-4005

July 3, 2006

Alaska Heart Institute, LLC
ATTN: Baxter Burton
Chief Executive Officer
3260 Providence Drive, Suite 537
Anchorage, AK 99508

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 12 to License No. 50-29111-01, **authorizing the release for unrestricted use of the following location of use (3340 Providence Drive, Suite 552, Anchorage, Alaska), according to the final status survey submitted to this office.** An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review this license carefully and be sure that you understand all conditions. If you have any questions, you may contact me at 817-860-8189.

As a reminder, you will need to prepare and submit to NRC a Final Status Survey (FSS) report for your location at 950 East Bogard, Suite 214, Wasilla, Alaska, when you vacate it. This survey report should include all areas within this facility where licensed materials were used and stored. The final status survey is one of the most important aspects of decommissioning a site since it is the primary document supporting the decision to release a facility or area within a facility for unrestricted use. Your survey should be performed in accordance with 10 CFR Part 30.36.

You should identify your swipe test results in terms of disintegrations per minute rather than counts per minute. Key the results to specific points on a facility diagram. Indicate the detection equipment that was used to assay the wipes, the method used to calibrate this equipment, the date of calibration, and specific calculations of instrument sensitivity. Optionally, you can choose to send your wipes to a vendor for analysis. Should you choose this option, you should provide the name and Agreement State or NRC license number of the vendor. Upon receipt of a satisfactory FSS report, we will issue an amendment to your license that will authorize the release of this facility for unrestricted use.

NRC's Regulatory Issue Summary (RIS) 2005-31, provides criteria to identify security-related sensitive information and guidance for handling and marking such documents. This ensures that potentially sensitive information is not made publicly available through NRC's electronic document system (ADAMS). The RIS may be located on the NRC Web site at: <http://www.nrc.gov/reading-rm/doc-collections/gen-comm/reg-issues/2005/>. Pursuant to NRC's RIS 2005-31, this letter and its accompanying materials license will be made publicly available.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC in writing of any change in mailing address.
3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
 - a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area; or
 - b. If you decide not to acquire or possess and use authorized material; or
 - c. When no principal activities under the license have been conducted for a period of 24 months.
4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:
 - a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);
 - b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;
 - c. The licensee's mailing address changes;
 - d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or
 - e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.
5. Request and obtain a license amendment before you:
 - a. Change Radiation Safety Officers;
 - b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;

- c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or
 - d. Change the name or ownership of your organization.
6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the NRC Enforcement Policy.

The NRC no longer publishes the NRC Rules and Regulations loose leaf supplements due to budget constraints. However, an electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. To view these regulations, highlight "Electronic Reading Room" and choose "Regulations" on the drop down menu. An electronic version of the NUREG-1556 Series publications is also available on the NRC Web site. To view these guidance documents, highlight "Electronic Reading Room"; choose "All Document Types" on the drop down menu; scroll down to "NUREG-Series Publications"; and select "Publications Prepared by the NRC Staff". Then, choose "NUREG-1556" from the table and select the appropriate volume(s) for your license type.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at <http://www.nrc.gov/reading-rm/adams.html>.

Thank you for your cooperation.

Sincerely,

/RA/

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Licensing Branch

Docket: 030-34474
License: 50-29111-01
Control: 471008

Enclosure: As stated

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Alaska Heart Institute, LLC</p> <p>2. 3260 Providence Drive, Suite 537 Anchorage, Alaska 99508</p>	<p>In accordance with letter dated June 1, 2006</p> <p>3. License number 50-29111-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date September 30, 2012</p> <hr/> <p>5. Docket No. 030-34474 Reference No.</p>
--	---

- | | | |
|--|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>E. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any, except generators</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> |
|--|--|---|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at:
- A. 950 East Bogard, Suite 214, Wasilla, Alaska,
- B. 3841 Piper Street, Suite T1-057, Anchorage, Alaska, and
- C. 2490 South Woodworth Loop, Suite 250, Palmer, Alaska
11. The Radiation Safety Officer for this license is Alan E. Skolnick, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user and/or authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
50-29111-01

Docket or Reference Number
030-34474

Amendment No. 12

B. The following individuals are authorized users for the materials and uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Mark A. Selland, M.D.	35.200
Mario Binder, M.D.	35.200
Alan E. Skolnick, M.D.	35.200
Julee K. Holyater, M.D.	35.100 and 35.200
Bradley K. Cruz, M.D.	35.100 and 35.200
Lester B. Lewis, M.D.	35.100 and 35.200
Lawrence P. Wood, M.D.	35.100 and 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
50-29111-01Docket or Reference Number
030-34474

Amendment No. 12

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated as May 10, 2002
 - B. Facsimile dated September 5, 2002
 - C. Letter dated January 15, 2004
 - D. Letter dated February 8, 2006
 - E. Letter dated March 14, 2006
 - F. Letter dated June 1, 2006



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 3, 2006By: /RA/
Roberto J. Torres, Senior Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011